NCT07490691 (PH-GRIEF) is a NA clinical trial of Painhunting Therapy in Loss-Related Depression, sponsored by Painhunting LLP.

Who is sponsoring NCT07490691?

NCT07490691 is sponsored by Painhunting LLP.

What drugs are being tested in NCT07490691?

Interventions in NCT07490691: Painhunting Therapy.

What condition does NCT07490691 study?

NCT07490691 studies Loss-Related Depression, Interpersonal Loss, Complicated Grief.

Is NCT07490691 still recruiting?

NCT07490691 is currently recruiting now. Last updated 7 April 2026.

Last reviewed 2026-04-07 · How we verify

NCT07490691: PH-GRIEF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Painhunting Therapy for Interpersonal Loss-Related Depression

Recruiting now NA Last updated 7 April 2026

What this trial tests

NA trial testing Painhunting Therapy in Loss-Related Depression in 72 participants. Currently enrolling.

Timeline

23 March 2026

Primary endpoint
31 August 2026

30 October 2026

Quick facts

Lead sponsor	Painhunting LLP
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	72
Start date	23 March 2026
Primary completion	31 August 2026
Estimated completion	30 October 2026
Sites	1 location across Kazakhstan

Drugs / interventions tested

Painhunting Therapy

Conditions studied

Loss-Related Depression — all drugs for Loss-Related Depression →
Interpersonal Loss — all drugs for Interpersonal Loss →
Complicated Grief — all drugs for Complicated Grief →

Sponsor

Painhunting LLP

Who can join

Adults 18 to 65, any sex, with Loss-Related Depression or Interpersonal Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot randomized controlled trial evaluates the efficacy of Painhunting therapy, a brief structured psychotherapy, for adults with significant interpersonal loss and comorbid depressive symptoms in Kazakhstan. Seventy-two participants will be randomly assigned to receive either immediate Painhunting therapy (3 sessions over 3-4 weeks) or a 4-week waitlist control condition. Therapy is delivered in-person in Astana or remotely via secure video conferencing (Zoom). Therapy sessions will be delivered by five trained Painhunting practitioners under the supervision of the Principal Investigator. The primary outcomes are changes in depression severity (PHQ-9) and complicated grief symptoms (ICG) from baseline to post-treatment. Secondary outcomes include anxiety, PTSD symptoms, and functional disability. All waitlist participants receive treatment after the waiting period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07490691 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Painhunting LLP
Last refreshed: 7 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07490691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing